

Financial news for APRI dated on 2019-01-25: The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

Financial news for APRI dated on 2019-01-15: Apricus Biosciences Shareholders Approve Merger Deal With Seelos Therapeutics

Financial news for APRI dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for APRI dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for APRI dated on 2018-12-14: Apricus Biosciences Reports Adjournment Of Special Meeting Of Shareholders To New Date Of Jan. 4, 2019

Financial news for APRI dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for APRI dated on 2018-10-31: Apricus Biosciences, Inc Q3 EPS \$(0.12) Up From \$(0.29) YoY

Financial news for APRI dated on 2018-10-17: Apricus Biosciences Says on October 16, Co & Seelos Entered Securities Purchase Agreement

Financial news for APRI dated on 2018-09-27: 13D From Armistice Capital Shows New 16.3% Stake In Apricus Biosciences

Financial news for APRI dated on 2018-09-11: Seeing Notable After-Hours Movement In Multiple Penny Stocks

Financial news for APRI dated on 2018-08-09: Apricus Biosciences Q2 EPS \$(0.10) Beats \$(0.12) Estimate

Financial news for APRI dated on 2018-08-01: 65 Biggest Movers From Yesterday

Financial news for APRI dated on 2018-07-31: 52 Stocks Moving In Tuesday's Mid-Day Session

Financial news for APRI dated on 2018-07-31: Apricus Therapeutics Shares Down 13% After Rising Yesterday On News Co. Will Merge With Seelos Therapeutics

Financial news for APRI dated on 2018-07-30: Apricus Biosciences Shares Up 32% Premarket After Co. Announces Signing Of Definitive Agreement To Merge With Privately-Held Seelos Therapeutic, Inc. In All-Stock Deal; Seelos Shareholders Will Receive APRI Common Shares And Own Approximately 86% Of Merge

Financial news for APRI dated on 2018-07-30: Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics In All-Stock Transaction; Apricus Shareholders To Own ~14% Of The Combined Co. With Seelos Owning ~86% Of The Combined Co.

Financial news for APRI dated on 2018-05-03: Apricus Biosciences Q1 EPS \$(0.14) Misses \$(0.12) Estimate

Financial news for APRI dated on 2018-04-17: 38 Biggest Movers From Yesterday

Financial news for APRI dated on 2018-04-16: Apricus Biosciences 8-K Shows Co. Received Nasdaq Staff Deficiency Letter Related To Minimum Bid Price Of \$1 Requirement; Co. Has 180 Calendar Days To Comply

Financial news for APRI dated on 2018-04-16: Mid-Afternoon Market Update: Dow Rises 300 Points; Apricus Biosciences Shares Plummet

Financial news for APRI dated on 2018-04-16: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for APRI dated on 2018-04-16: Mid-Day Market Update: Crude Oil Down Over 1%; Eldorado Resorts Shares Surge

Financial news for APRI dated on 2018-04-16: Benzinga Pro's 5 Stocks To Watch Today

Financial news for APRI dated on 2018-04-16: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for APRI dated on 2018-04-16: Apricus Biosciences Shares Resume Trade, Now Up 7.1%

Financial news for APRI dated on 2018-04-16: Apricus Biosciences Shares To Resume Trade At 7:30 a.m. EDT

Financial news for APRI dated on 2018-04-16: Apricus Biosciences to Resume Trading at 7:30 AM ET

Financial news for APRI dated on 2018-04-16: Apricus Biosciences Says Board Has Determined For Evaluation Of Strategic Alternatives

Financial news for APRI dated on 2018-04-16: UPDATE: Apricus Says Cost, Timeline Associated With FDA's Outline For Vitaros Exceeds Co.'s Current Resources, Ability To Raise Added Capital; Mgmt. Has Initiated Discussions With Interested Parties For Partnership

Financial news for APRI dated on 2018-04-16: UPDATE: Apricus Says FDA Confirmed Co. Should Develop New Vitaros Formulation Which Reduces Concentration Of DDAIP.HCI From 2.5% To 0.5%

Financial news for APRI dated on 2018-04-16: Apricus Biosciences Reports Prelim. End Of Review Meeting Minutes Support Plan To Address Issues In FDA's Feb. 15 CRL For Vitaros NDA

Financial news for APRI dated on 2018-04-16: Apricus Biosciences Halted News Pending

Financial news for APRI dated on 2018-03-28: Apricus Biosciences Shares Down 33.7% After Co. Earlier Priced 7.1M Share Offering At \$0.50/Share

Financial news for APRI dated on 2018-03-28: Apricus Biosciences Prices ~7.1M Shares At \$0.50/Share

Financial news for APRI dated on 2018-03-27: Apricus Biosciences Reports Offering Of Common Stock, No Size Disclosed

Financial news for APRI dated on 2018-03-26: Apricus Biosciences Announced Its End-Of-Review Meeting With FDA To Discuss New Drug Application For Vitaros Will Be Held On April 12, 2018

Financial news for APRI dated on 2018-03-01: Apricus Biosciences Reports Q4 EPS \$(0.16) vs \$(0.15) Est., No Sales

Financial news for APRI dated on 2018-02-28: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for APRI dated on 2018-02-20: What's Next For Apricus Biosciences' Vitaros?

Financial news for APRI dated on 2018-02-20: 45 Biggest Movers From Friday

Financial news for APRI dated on 2018-02-16: Mid-Afternoon Market Update: Blackline Surges After Q4 Results; Moleculin Biotech Shares Slide

Financial news for APRI dated on 2018-02-16: Apricus Biosciences Shares Down 67.6% After Failing to Obtain FDA Approval For Vitaros

Financial news for APRI dated on 2018-02-16: H.C. Wainwright Downgrades Apricus Biosciences to Neutral

Financial news for APRI dated on 2018-02-16: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for APRI dated on 2018-02-16: Mid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet

Financial news for APRI dated on 2018-02-16: Mid-Morning Market Update: Markets Open Higher; Coca-Cola Sales Top Expectations

Financial news for APRI dated on 2018-02-16: Apricus Biosciences Halted On Circuit Breaker, Down 60.5% At \$1.26

Financial news for APRI dated on 2018-02-16: Benzinga Pro's 5 Stocks To Watch Today

Financial news for APRI dated on 2018-02-16: Shares of Apricus Biosciences are Down 65.8% After the FDA Said it would Not Approve Apricus' NDA for Vitaros in its Current Form

Financial news for APRI dated on 2018-02-16: Apricus Biosciences Says the FDA Will Not Approve its NDA for Vitaros in its Current Form

Financial news for APRI dated on 2018-02-16: Apricus Biosciences Halted, News Pending

Financial news for APRI dated on 2018-02-16: 46 Biggest Movers From Yesterday

Financial news for APRI dated on 2018-02-15: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for APRI dated on 2018-02-15: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for APRI dated on 2018-02-13: 9 Stocks Moving In Tuesday's After-Hours Session

Financial news for APRI dated on 2018-02-13: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for APRI dated on 2018-02-13: 33 Biggest Movers From Yesterday

Financial news for APRI dated on 2018-02-05: Apricus Biosciences Shares Up 7.21% On High Volume; Apricus Spokesperson Tells Benzinga Co. Unaware Of Any Specific Catalyst Driving Today's Price Action, Highlights FDA PDUFA Date For Vitaros On Or Around Feb 17 As 'Next Known Catalyst'

Financial news for APRI dated on 2018-02-05: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for APRI dated on 2018-02-05: Apricus Biosciences Shares Up 9.5% Mon. On No News; Stock Has Been Caught In A \$0.20-\$0.30 Trading Range Since End Of Jan., High Near \$2.54, Low Near \$2.22

Financial news for APRI dated on 2018-02-05: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for APRI dated on 2018-01-31: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Financial news for APRI dated on 2018-01-16: 38 Biggest Movers From Friday

Financial news for APRI dated on 2018-01-08: 40 Biggest Movers From Friday

Financial news for APRI dated on 2018-01-05: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for APRI dated on 2018-01-05: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for APRI dated on 2018-01-03: Apricus Biosciences Shares Up 6.45% Amid Some Social Media Mention Of Positive Sentiment Ahead Of February 17 FDA PDUFA Date For Vitaros NDA

Financial news for APRI dated on 2018-01-03: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for APRI dated on 2018-01-03: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for APRI dated on 2017-11-02: Apricus Biosciences Reports Q3 EPS \$(0.29) s \$(0.16) Est

Financial news for APRI dated on 2017-09-25: S-3 From Apricus Therapeutics Shows Registration For ~3.312M Share Common Stock Offering Via Selling Holders

Financial news for APRI dated on 2017-09-20: 13G Filing Shows Armistice Capital Reporting 9.6% Stake In Apricus Biosciences

Financial news for APRI dated on 2017-09-11: 8-K From Apricus Biosciences Shows Co. Entered Securities Purchase Deal With Certain Investors For Sale By Co. Of ~2.137M Shares At \$1.7275/Share, Warrants To Buy Up To ~1.07M Shares

Financial news for APRI dated on 2017-09-11: Apricus Biosciences Announces \$3.7M At the Market Private Placement

Financial news for APRI dated on 2017-08-31: Apricus Biosciences Reports FDA Acknowledged Vitaros Class 2 NDA Resubmission

Financial news for APRI dated on 2017-08-29: Apricus Biosciences Files NDA Resubmission for Vitaros, Expects PDUFA Date in Q1 2018

Financial news for APRI dated on 2017-08-22: Apricus Biosciences Registers to Offer ~866K Shares of Common Stock

Financial news for APRI dated on 2017-07-25: Apricus Bio Spikes to High of \$1.21 on

Volume

Financial news for APRI dated on 2017-05-11: Apricus Biosciences Reports Q1 EPS \$1.04 vs \$1.25 Est.

Financial news for APRI dated on 2017-05-04: Apricus Biosciences Announces Initiation of Vitaros Drug-Device Human Factors Study

Financial news for APRI dated on 2017-04-26: Benzinga's Top Upgrades, Downgrades For April 26, 2017

Financial news for APRI dated on 2017-04-26: Rodman & Renshaw Initiates Coverage On Apricus Biosciences with Buy Rating, Announces \$4.00 Price Target

Financial news for APRI dated on 2017-04-21: 15 Biggest Mid-Day Losers For Friday

Financial news for APRI dated on 2017-04-21: Apricus Biosciences Prices Offering of 5.03M Units at \$1.40/Unit

Financial news for APRI dated on 2017-04-21: Apricus Biosciences Prices 5M Unit Public Offering @\$1.40/Unit

Financial news for APRI dated on 2017-04-20: 18 Biggest Mid-Day Losers For Thursday

Financial news for APRI dated on 2017-04-17: 15 Biggest Mid-Day Losers For Monday

Financial news for APRI dated on 2017-04-17: Apricus Biosciences Files For Offering Of Up To \$6M of Units, Consisting Of 1 Share Of Stock, Warrant To Purchase 0.75 Shares

Financial news for APRI dated on 2017-04-12: 11 Biggest Mid-Day Gainers For Wednesday

Financial news for APRI dated on 2017-04-12: Apricus Pops to High of \$2.24 on Volume

Financial news for APRI dated on 2017-03-30: Apricus Biosciences Files S-1 For \$6.9M Stock Offering

Financial news for APRI dated on 2017-03-20: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for APRI dated on 2017-03-14: Apricus Gaps Down to Low of \$1.65 on Volume

Financial news for APRI dated on 2017-03-13: Apricus Biosciences Reports Q4 EPS \$(0.04) vs. \$(0.15) Est.

Financial news for APRI dated on 2017-03-13: Earnings Scheduled For March 13, 2017

Financial news for APRI dated on 2017-03-09: Apricus Biosciences Shares Trading Up 24% Premarket On Yesterday's Sale Of Vitaros Assets To Ferring

Financial news for APRI dated on 2017-03-08: Apricus Shares Resume Trade, Now Up 49%

Financial news for APRI dated on 2017-03-08: Apricus Shares to Resume Trade at 4:30 p.m. EST

Financial news for APRI dated on 2017-03-08: Apricus Biosciences Reports Sale of Ex-US Vitaros Assets, Rights to Ferring, Expects to Receive ~\$12.7M from Ferring

Financial news for APRI dated on 2017-03-08: Apricus Shares Halted News Pending

Financial news for APRI dated on 2017-02-09: Apricus Biosciences Reports Received Positive Nasdaq Listing Determination

Financial news for APRI dated on 2017-01-20: Apricus Biosciences Spikes to High of \$2.83 on Volume

Financial news for APRI dated on 2017-01-19: 15 Biggest Mid-Day Losers For Thursday

Financial news for APRI dated on 2017-01-19: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for APRI dated on 2017-01-18: Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast

Financial news for APRI dated on 2017-01-18: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for APRI dated on 2017-01-18: Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble

Financial news for APRI dated on 2017-01-18: Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views

Financial news for APRI dated on 2017-01-18: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for APRI dated on 2017-01-18: Apricus Biosciences +31% Premarket @\$1.98; Co Announced Approval of Vitaros in Mexico to Treat ED

Financial news for APRI dated on 2017-01-18: Apricus Biosciences Announces Approval of Vitaros For Treatment Of Erectile Dysfunction, Will Launch In Mexico & Argentina In Q2

Financial news for APRI dated on 2016-12-27: Apricus Biosciences Reports the Launch of Vitaros for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals

Financial news for APRI dated on 2016-12-13: 15 Biggest Mid-Day Losers For Tuesday

Financial news for APRI dated on 2016-11-18: 18 Biggest Mid-Day Losers For Friday

Financial news for APRI dated on 2016-11-18: Mid-Morning Market Update: Markets Mostly Flat; Foot Locker Profit Beats Estimates

Financial news for APRI dated on 2016-11-18: Apricus Biosciences Issues Update on Vitaros NDA Following Receipt of FDA Feedback: Reaffirms Plans to Re-submit Vitaros US NDA

Financial news for APRI dated on 2016-11-08: Apricus Biosciences Sends Message To Shareholders, Says Due To Disappointing fispemifene Clinical Results, Will Focus On Fostering And Expanding Vitaros Partnerships

Financial news for APRI dated on 2016-11-08: Apricus Biosciences Reports Q3 EPS \$(0.19) vs \$(0.60) Est., Sales \$4.317M vs \$1.91M Est.

Financial news for APRI dated on 2016-11-02: 18 Biggest Mid-Day Losers For Wednesday

Financial news for APRI dated on 2016-11-02: Stocks Hitting 52-Week Lows

Financial news for APRI dated on 2016-10-26: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for APRI dated on 2016-10-26: Apricus Biosciences Announces Approval of Vitaros for the Treatment of Erectile Dysfunction in Greece

Financial news for APRI dated on 2016-10-24: Mid-Afternoon Market Update: ACCO Brands Gains On Earnings Beat; Boise Cascade Shares Down

Financial news for APRI dated on 2016-10-24: Mid-Morning Market Update: Markets Open Higher; AT&T to Acquire Time Warner For \$85.4B

Financial news for APRI dated on 2016-10-20: Apricus Biosciences Announces 1-For-19 Reverse Stock Split

Financial news for APRI dated on 2016-09-28: 8-K from Apricus Shows Mutual Agreement to Terminate Certain Securities Purchase Deal; Entered New Deal for Sale by Co. of ~13.14M Shares at \$0.345/Share

Financial news for APRI dated on 2016-09-23: Apricus Biosciences Reports \$4.6M Registered Direct Offering

Financial news for APRI dated on 2016-09-14: Top Performing Industries For September 14, 2016

Financial news for APRI dated on 2016-09-08: Apricus Biosciences Gets Approval For Vitaros in Argentina

Financial news for APRI dated on 2016-09-06: Apricus Biosciences Announces Launch of Erectile Dysfunction Treatment in Portugal, Ireland and Poland

Financial news for APRI dated on 2016-08-05: 18 Biggest Mid-Day Losers For Friday

Financial news for APRI dated on 2016-08-05: Worst Performing Industries For August 5, 2016

Financial news for APRI dated on 2016-08-04: Apricus Biosciences Reports Q2 EPS \$(0.05) vs. Est. \$(0.08), Rev. \$464K vs. Est. \$1.52M

Financial news for APRI dated on 2016-07-27: Apricus Biosciences Reports Approval of Vitaros for Treatment of ED in Lebanon

Financial news for APRI dated on 2016-07-25: Apricus Biosciences Reports Further Expansion of Existing Vitaros Partnership with Ferring Pharma in Europe, Asia

Financial news for APRI dated on 2016-05-09: Apricus Biosciences EPS (\$0.09) vs \$(0.09) est, Revenue \$626K vs 920K est

Financial news for APRI dated on 2016-04-06: Apricus Biosciences To Focus On Vitaros Rev. Growth, US NDA Re-Submission & Additional Commercial Launches Globally While Reducing Operating Expenses

Financial news for APRI dated on 2016-03-30: Stocks Hitting 52-Week Lows

Financial news for APRI dated on 2016-03-28: Mid-Afternoon Market Update: Dow Jumps 50 Points; Pandora Shares Slide

Financial news for APRI dated on 2016-03-28: Apricus Biosciences Plunges 50% Following 'Disappointing' Phase 2B Data

Financial news for APRI dated on 2016-03-28: Mid-Day Market Update: Qlik Technologies Surges Amid Potential Sale; VirtualScopics Shares Decline

Financial news for APRI dated on 2016-03-28: Stocks Hitting 52-Week Lows

Financial news for APRI dated on 2016-03-28: Mid-Morning Market Update: Markets Mostly Flat; Cal-Maine Foods Profit Beats Views

Financial news for APRI dated on 2016-03-28: Apricus Biosciences Shares Trading Down ~50% at \$0.72/Share On Discontinuation Of Fispemifene In Secondary Hypogonadism

Financial news for APRI dated on 2016-03-28: Apricus Biosciences Resumes Trading

Financial news for APRI dated on 2016-03-28: Apricus Fails To Achieve Statistical Significance In Clinical Benefit Endpoints, Despite Raised Testosterone Levels

Financial news for APRI dated on 2016-03-28: Apricus Biosciences Halted, News Pending

Financial news for APRI dated on 2016-03-15: Taglich Brothers Maintains Speculative Buy on Apricus Biosciences, Lowers PT to \$2.95

Financial news for APRI dated on 2016-03-09: Apricus Bioscience Reports Q4 EPS \$(0.05) Vs Est \$(0.11), Sales \$2.6M Vs Est \$1.81M

Financial news for APRI dated on 2016-03-09: Apricus Biosciences Reports Q4 EPS \$(0.05) vs. Est. \$(0.11), Rev. \$2.6M vs. Est. \$1.81M

Financial news for APRI dated on 2016-03-09: Earnings Scheduled For March 9, 2016

Financial news for APRI dated on 2016-01-13: Apricus Biosciences Reports \$10M Direct Offering

Financial news for APRI dated on 2016-01-06: UPDATE: Apricus Says Sees Resubmitting NDA for Vitaros' Approval in US During 2H'16

Financial news for APRI dated on 2016-01-06: UPDATE: Apricus Says Sees Initiation of Phase 2b At-Home Dosing Clinical Trial with RayVa in 2H'16

Financial news for APRI dated on 2016-01-06: UPDATE: Apricus Says Top-Line Phase 2b Data for Fispemifene Expected in Q1

Financial news for APRI dated on 2015-12-09: Benzinga's Top Downgrades

Financial news for APRI dated on 2015-12-09: Sterne Agee CRT Downgrades Apricus Biosciences to Neutral

Financial news for APRI dated on 2015-12-03: UPDATE: For Each Share of American Residential Properties, Will Exchange 1.135 Common Shares of American Homes 4 Rent

Financial news for APRI dated on 2015-12-01: Apricus Biosciences Confirms Clinical Strategy for Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene

Financial news for APRI dated on 2015-11-05: Apricus Biosciences Reports Q3 EPS \$(0.10) vs \$(0.11) Est., Sales \$1.3M vs \$1.42M Est.

Financial news for APRI dated on 2015-10-28: Apricus Biosciences Completes Enrollment in Phase 2b Clinical Trial for Fispemifene in Men with Symptomatic Secondary Hypogonadism

Financial news for APRI dated on 2015-10-01: Apricus Biosciences and Ferring Pharmaceuticals Sign Exclusive Distribution Agreement to Market Topical Erectile Dysfunction Cream Vitaros(TM) in Latin American Countries

Financial news for APRI dated on 2015-09-17: Apricus Reports Top-Line Phase 2a Data for RayVa, Its Topical Treatment for Raynaud's Phenomenon

Financial news for APRI dated on 2015-09-17: Apricus Reports Top-Line Phase 2a Data for RayVa(TM), Its Topical Treatment for Raynaud's Phenomenon

Financial news for APRI dated on 2015-09-10: Morning Market Gainers

Financial news for APRI dated on 2015-09-10: Apricus Biosciences Enters Into License Agreement With Allergan for the U.S. Rights to Vitaros

Financial news for APRI dated on 2015-08-20: Mid-Day Market Update: Thursday's Movers, Feds Meet But No Answers Met

Financial news for APRI dated on 2015-08-19: Apricus Announces Seeking Global Partner for Femprox for Female Sexual Dysfunction

Financial news for APRI dated on 2015-08-05: Apricus Biosciences Reports Q2 EPS \$(0.10) vs. Est. \$(0.13)

Financial news for APRI dated on 2015-06-15: US Stock Futures Signal Lower Start On Wall Street

Financial news for APRI dated on 2015-06-15: Apricus Biosciences Announces Last Patient Enrolled in RayVa Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma

Financial news for APRI dated on 2015-06-01: Apricus Biosciences Enrolls Patients in Phase 2b Clinical Trial for Fispemifene in Men With Symptomatic Secondary Hypogonadism

Financial news for APRI dated on 2015-05-28: Apricus Biosciences Reports the Launch of Its Novel Topical Treatment for Erectile Dysfunction in France by Laboratoires Majorelle

Financial news for APRI dated on 2015-05-06: Apricus Biosciences Launches Novel Topical Treatment for Erectile Dysfunction in Spain

Financial news for APRI dated on 2015-03-16: UPDATE: Apricus Biosciences Says Plans to Pursue Out-License Opportunities for Vitaros, Will Begin Phase 2b Trial of Fispemifene During Q1'16

Financial news for APRI dated on 2015-03-16: Apricus Biosciences Offers Corporate Update, Reports Results: Q4 Loss of \$0.40/Share vs Loss of \$0.12/Share Est., Sales \$1.9M vs \$670K Est.

Financial news for APRI dated on 2015-02-23: Taglich Brothers Initiates Coverage on Apricus Biosciences at Speculative Buy, PT \$5.80 undefined

Financial news for APRI dated on 2015-02-11: Apricus Biosciences Reports 411M Registered Direct Offering with Sarissa Capital

Financial news for APRI dated on 2015-02-03: Apricus Biosciences Expands Exclusive License Agreement With Existing Partner to Market Vitaros in Select Asia-Pacific Countries

Financial news for APRI dated on 2015-02-02: 7 U.S. Health Care Penny Stocks With Upside Potential Greater Than 100%

Financial news for APRI dated on 2015-01-28: Morning Market Gainers

Financial news for APRI dated on 2015-01-28: Wednesday Morning Movers: Apple Climbing Following Record-Breaking Earnings

Financial news for APRI dated on 2015-01-27: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa

Financial news for APRI dated on 2014-12-22: Apricus Biosciences Offers Year-End '14 Update; in '15 Plans to Advance Clinical Pipeline, Further Commercialization of ED Drug Vitaros(R)

Financial news for APRI dated on 2014-12-15: UPDATE: Apricus Biosciences Appoints Barbara Troupin As CMO

Financial news for APRI dated on 2014-12-15: Apricus Biosciences Announces Resignation Of SVP, CFO Martin; Apricus Biosciences Appoints CMO

Financial news for APRI dated on 2014-12-04: Apricus Biosciences Reports First Patient Enrolled in Phase 2a Trial for RayVa(TM) in Patients with Raynaud's

Financial news for APRI dated on 2014-12-02: Apricus Biosciences Appoints Brian Dorsey As Chief Development Officer

Financial news for APRI dated on 2014-11-10: Apricus Biosciences, Inc Reports Q3 EPS of \$(0.08) vs \$(0.10) Est

Financial news for APRI dated on 2014-10-28: Cantor Fitzgerald Downgrades Apricus Biosciences, Inc to Hold

Financial news for APRI dated on 2014-10-24: Apricus Biosciences CEO Pascoe Buys 12,000 Shares @\$1.51/Share -Form 4

Financial news for APRI dated on 2014-10-20: Morning Market Movers

Financial news for APRI dated on 2014-10-20: Apricus License US Rights for Fispemifene, a Phase 2b Ready Asset, from Forendo Pharma for Upfront License Fee of \$12.5M

Financial news for APRI dated on 2014-10-13: Morning Market Losers

Financial news for APRI dated on 2014-10-13: Apricus Biosciences Receives Notice of Allowance of US Patent Application for RayVa

Financial news for APRI dated on 2014-08-18: Apricus Biosciences Announces Launch of Vitaros in Germany

Financial news for APRI dated on 2014-08-12: S-3 Filing from Apricus Biosciences Shows \$100M Mixed Securities Shelf

Financial news for APRI dated on 2014-08-12: Apricus Biosciences, Inc Reports Q2 EPS of \$0.05 vs \$(0.04) Est

Financial news for APRI dated on 2014-08-12: Apricus Biosciences Announces Sales of 1.159 Shares to Aspire Capital For \$2M And Will Purchase Up To \$20M Over Next 2 Years

Financial news for APRI dated on 2014-08-08: Apricus Biosciences Announces Partnership With Scleroderma to Partner For Research

Financial news for APRI dated on 2014-08-04: Apricus Biosciences Announces Launch of Vitaros in Sweden

Financial news for APRI dated on 2014-05-27: Cantor Fitzgerald Upgrades Apricus Biosciences, Inc to Buy

Financial news for APRI dated on 2014-05-12: Apricus Biosciences, Inc Reports Q1 EPS of \$(0.09) vs \$(0.03) Est

Financial news for APRI dated on 2014-05-12: Apricus Receives FDA Clearance To Start Clinical Trial of RayVa

Financial news for APRI dated on 2014-04-24: Apricus Biosciences Announces National Phase Approval for Vitaros in Spain

Financial news for APRI dated on 2014-04-16: UPDATE: Apricus Shares Rise 21% as Takeda Accepts First Shipment of Vitaros

Financial news for APRI dated on 2014-04-03: Apricus Biosciences Announces National Phase Approval for Vitaros in Luxembourg

Financial news for APRI dated on 2014-03-17: Apricus Biosciences, Inc Reports Q4 EPS of \$(0.04) vs \$(0.06) Est

Financial news for APRI dated on 2014-03-17: Earnings Scheduled For March 17, 2014

Financial news for APRI dated on 2014-01-23: Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream, Vitaros In Belgium

Financial news for APRI dated on 2013-12-16: Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus to Receive Up to \$63M in Milestone Payments

Financial news for APRI dated on 2013-12-11: Apricus Elects Kleanthis G. Xanthopoulos as New Chairman

Financial news for APRI dated on 2013-11-25: Apricus Biosciences Reports National Phase Approval for Vitaros in Italy, On Track for European Launch in 2014, Added Partnerships Expected in Q4

Financial news for APRI dated on 2013-11-13: Apricus Announces Laboratoires Majorelle to Market Vitaros in France, Monaco and Certain African Countries

Financial news for APRI dated on 2013-10-10: Apricus Registers Up to 395,018 Shares for Selling Holders

Financial news for APRI dated on 2013-10-07: Apricus Reports National Phase Approval of ED Cream in Germany

Financial news for APRI dated on 2013-08-28: Ascendant Capital Maintains Strong Buy on Apricus Biosciences, Inc, Lowers PT to \$4.00

Financial news for APRI dated on 2013-08-23: UPDATE: Cantor Fitzgerald Initiates Coverage on Apricus Biosciences on Cautious Stance

Financial news for APRI dated on 2013-08-23: Benzinga's Top Initiations

Financial news for APRI dated on 2013-08-23: Cantor Fitzgerald Initiates Coverage on Apricus Biosciences, Inc at Hold, Announces \$2.00 PT

Financial news for APRI dated on 2013-08-12: Apricus Biosciences Reports Vitaros National Phase Approvals in UK, Sweden

Financial news for APRI dated on 2013-06-10: Apricus Wins EU Approval for Vitaros for ED

Financial news for APRI dated on 2013-05-23: Apricus Biosciences Shares Plunge as 6M Shares Priced at \$2.85/Share

Financial news for APRI dated on 2013-05-22: Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants

Financial news for APRI dated on 2013-05-10: Earnings Scheduled For May 10, 2013

Financial news for APRI dated on 2013-04-01: Apricus Biosciences Sells Totect for Bicodex Labs Unit

Financial news for APRI dated on 2013-03-18: Apricus Biosciences Names Richard Pascoe as CEO

Financial news for APRI dated on 2013-03-14: Apricus Reports Ceasing of Financing of French Subsidiaries

Financial news for APRI dated on 2013-01-03: Apricus Biosciences Reports on Corporate Goals for 2013

Financial news for APRI dated on 2012-11-06: Apricus Biosciences Says CEO Bassam Damaj to Leave, Co. Names CFO Martin as Interim Chief

Financial news for APRI dated on 2012-10-18: Apricus Biosciences Receives \$2.5M Payment From Abbott Laboratories

Financial news for APRI dated on 2012-10-01: Benzinga's Top Pre-Market Gainers

Financial news for APRI dated on 2012-10-01: Apricus Biosciences Announces Intent to File NDS for MycoVa in Canada

Financial news for APRI dated on 2012-09-13: A Peek Into The Market Before The Trading Starts

Financial news for APRI dated on 2012-09-13: Apricus Biosciences Subsidiary NexMed and Takeda Pharmaceuticals Sign Agreement to Market Vitaros in UK

Financial news for APRI dated on 2012-07-23: UPDATE: Ascendant Capital Markets Initiates Strong Buy on Apricus Biosciences; Major Inflection Point

Financial news for APRI dated on 2012-07-23: Ascendant Capital Markets Initiates Coverage on Apricus Biosciences at Strong Buy, Announces PT of \$6

Financial news for APRI dated on 2012-07-17: Apricus Biosciences Issues Statement Regarding Registration of Shares Related to Finesco/Scomedica and PediatRx Transactions

Financial news for APRI dated on 2012-06-14: Apricus Biosciences Submits Response to Swissmedic for Its Vitaros(R) Market Application for Erectile Dysfunction

Financial news for APRI dated on 2012-06-06: Roth Capital Initiates Apricus Biosciences at Buy

Financial news for APRI dated on 2012-05-25: Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances

Financial news for APRI dated on 2012-05-22: Apricus Biosciences Granted Regulatory Guidance With FDA for MycoVa(TM) for the Treatment of Onychomycosis

Financial news for APRI dated on 2012-05-21: Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder

Financial news for APRI dated on 2012-05-11: Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis

Financial news for APRI dated on 2012-04-26: Apricus Biosciences Receives Notice of Issuance for First Prevonco(TM) Patent in the United States

Financial news for APRI dated on 2012-03-22: Apricus Biosciences Announces Allowance of a NexACT Technology-Based Patent in Europe for the Manufacture of DDAIP

Financial news for APRI dated on 2012-03-19: Dawson James Securities Maintains Apricus Biosciences at Buy, Lowers PT from \$8.25 to \$5.5

Financial news for APRI dated on 2012-02-15: Apricus Bioscience's Wholly-Owned Subsidiary NexMed Signs Exclusive German Collaboration for Vitaros for Erectile Dysfunction

Financial news for APRI dated on 2012-02-09: Apricus Biosciences Prices \$20.0M Public Offering of Common Stock and Warrants

Financial news for APRI dated on 2012-02-08: Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants; Size Not Given

Financial news for APRI dated on 2012-01-27: Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrix for U.S. Co-Promotion of GRANISOL(R) (Granisetron) Oral Solution and AQUORAL(TM) Spray and Purchase of Non-U.S. Rights to GRANISOL(R)

Financial news for APRI dated on 2012-01-10: Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa in the Middle East and the Gulf

Financial news for APRI dated on 2012-01-09: Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros in Canada

Financial news for APRI dated on 2012-01-03: Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa for Onychomycosis

Financial news for APRI dated on 2012-01-03: Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada

Financial news for APRI dated on 2011-12-30: Apricus Biosciences Enters into Exclusive License Agreement with Stellar Pharmaceuticals to Market MycoVa in Canada

Financial news for APRI dated on 2011-12-16: Apricus Biosciences to Acquire Topotarget USA

Financial news for APRI dated on 2011-12-11: Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)

Financial news for APRI dated on 2011-12-08: Apricus Biosciences Announces Allowance of Additional NexACT Patent in Japan

Financial news for APRI dated on 2011-11-30: Apricus Biosciences Announces Podium Presentation of Efficacy and Clinical Safety Data for Vitaros at the European Sexual Society Medicine Conference

Financial news for APRI dated on 2011-11-21: Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors

Financial news for APRI dated on 2011-11-15: Apricus Biosciences Announces That Its NexACT Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA

Financial news for APRI dated on 2011-10-26: Angstrom Pharmaceuticals Announces Publication of the Discovery of the Cellular Target of Its A6 Phase II Clinical Compound Resulting From Its Joint Study With Apricus Biosciences

Financial news for APRI dated on 2011-10-19: Apricus Biosciences Announces Issuance of Korean Patent

Financial news for APRI dated on 2011-10-03: Apricus Biosciences Announces Korean Patent Approval for MycoVa for Nail Fungus

Financial news for APRI dated on 2011-09-02: Apricus Biosciences Admits Making Misleading Statements Citing FDA Product 'Approvals'

Financial news for APRI dated on 2011-08-31: Is Apricus' New Drug Worth It?

Financial news for APRI dated on 2011-08-31: Apricus Biosciences Receives FDA Clearance for Its Third OTC Drug Containing NexACT Technology

Financial news for APRI dated on 2011-08-23: Apricus Biosciences Announces FDA Clearance for Its Second OTC Anti-Itch Drug (Hydrocortisone-D Containing NexACT Technology

Financial news for APRI dated on 2011-08-18: Morning MoversApricus Biosciences Announces FDA Clearance for Its First Anti-Fungal OTC Drug (Tolnaftate-D(TM)) Containing NexACT(R) Technology

Financial news for APRI dated on 2011-08-15: Apricus Biosciences Announces Expansion of Its NexACT(R) Patent Portfolio

Financial news for APRI dated on 2011-08-08: Apricus Biosciences to File for Market Authorization to Sell Vitaros for Erectile Dysfunction in Latin America

Financial news for APRI dated on 2011-08-08: Apricus Biosciences to File for Market Authorization to Sell Vitaros for Erectile Dysfunction in Latin America

Financial news for APRI dated on 2011-08-04: Apricus Biosciences Provides Corporate Mid-Year Update

Financial news for APRI dated on 2011-07-19: Apricus Biosciences Files Marketing Application for Vitaros as a Treatment for Erectile Dysfunction in Switzerland

Financial news for APRI dated on 2011-07-06: Apricus Biosciences Sells Bio-Quant CRO Subsidiary to BioTox Sciences

Financial news for APRI dated on 2011-06-28: Apricus Biosciences' Marketing Application for Vitaros, for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe

Financial news for APRI dated on 2011-06-27: Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus

Financial news for APRI dated on 2011-06-17: Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra Litigation is Successful

Financial news for APRI dated on 2011-06-10: AUD/USD Weekly Fundamental Analysis for June 13- 17, 2011

Financial news for APRI dated on 2011-06-10: AUD/NZD Weekly Fundamental Analysis for June 13- 17, 2011

Financial news for APRI dated on 2011-06-02: Apricus Biosciences Appoints Steve Martin as Senior Vice President and Chief Financial Officer

Financial news for APRI dated on 2011-05-31: Apricus Biosciences Announces Issuance of Key Patent for RayVa for Raynaud's Phenomenon in Israel

Financial news for APRI dated on 2011-05-19: Apricus Biosciences Will Request Approval of Vitaros as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities

Financial news for APRI dated on 2011-04-28: Apricus Biosciences Requests Approval of Vitaros as a Treatment for Erectile Dysfunction in Europe (APRI)

Financial news for APRI dated on 2011-04-13: Apricus Biosciences Files for Orphan Drug Designation for RayVa

Financial news for APRI dated on 2011-03-31: Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug

Financial news for APRI dated on 2011-03-29: Hearing Deal With Top Pharma Company Could Be Near For Apricus Biosciences (APRI)

Financial news for APRI dated on 2011-03-08: Apricus Biosciences Announces Removal of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K and Increased Cash Reserves

Financial news for APRI dated on 2011-02-22: Apricus Bioscience Up 19%

Financial news for APRI dated on 2011-02-17: Apricus Biosciences and FDA Initiate PrevOnco SPA Phase III Clinical Protocol Discussion

Financial news for APRI dated on 2011-02-14: Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros in Israel for up to \$4.35M, Plus Royalties

Financial news for APRI dated on 2011-01-18: Top Performing Industries For January 18 (ARW, SVM, RUK, APRI)

Financial news for APRI dated on 2010-12-23: Apricus Bioscience Inc (NASDAQ)

Financial news for APRI dated on 2010-12-22: Apricus Biosciences and Bracco Sign Licensing Agreement

Financial news for APRI dated on 2010-11-23: Biotech Stock Mailbag: Aastrom BioSciences

Financial news for APRI dated on 2010-10-18: Apricus Bio Announces Patent Grant for Femprox In Japan

Financial news for APRI dated on 2010-10-11: Apricus Biosciences to Present at the PrecisionIR Informed Investors Forum Biotech, Healthcare and Pharma Virtual Conference on October 13

Financial news for APRI dated on 2010-10-05: Apricus Bio Closes Securities Offering, Raises over \$9.3 Million

Financial news for APRI dated on 2010-09-29: Three Biggest Losers On The NASDAQ Today (FALC, APRI, MLNK)

Financial news for APRI dated on 2010-09-29: APRI Announces 1.7 Million Units Pricing; Shares Plunge